Share on StockTwits

DexCom (NASDAQ:DXCM) Insider Jorge A. Valdes unloaded 16,000 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $43.56, for a total transaction of $696,960.00. Following the transaction, the insider now directly owns 217,487 shares of the company’s stock, valued at approximately $9,473,734. The sale was disclosed in a document filed with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $41.00.

DexCom (NASDAQ:DXCM) traded down 2.19% during mid-day trading on Tuesday, hitting $42.89. 713,681 shares of the company’s stock traded hands. DexCom has a 52-week low of $25.49 and a 52-week high of $49.83. The stock’s 50-day moving average is $38.86 and its 200-day moving average is $38.61. The company’s market cap is $3.237 billion. DexCom also was the recipient of unusually large options trading activity on Tuesday. Traders purchased 168 put options on the stock. This is an increase of approximately 118% compared to the typical volume of 77 put options.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share. The company’s revenue for the quarter was up 64.2% on a year-over-year basis. Analysts expect that DexCom will post $-0.31 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.